

Goat anti-PRKACA Antibody Peptide-affinity purified goat antibody Catalog # AF4369a

Specification

Goat anti-PRKACA Antibody - Product Information

Application Primary Accession Other Accession Reactivity Host Clonality Calculated MW WB, Pep-ELISA <u>P17612</u> <u>NP_002721.1</u>, <u>NP_997401.1</u>, <u>NP_001291278.1</u> Human Goat Polyclonal 40590

Goat anti-PRKACA Antibody - Additional Information

Gene ID 5566

Other Names

PRKACA; protein kinase, cAMP-dependent, catalytic, alpha; PKACA; PPNAD4; PKA C-alpha; cAMP-dependent protein kinase catalytic subunit alpha; protein kinase A catalytic subunit

Dilution WB~~1:1000 Pep-ELISA~~N/A

Format

Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. Aliquot and store at -20°C. Minimize freezing and thawing.

Immunogen

This antibody is expected to recognize all three reported isoforms (NP_002721.1; NP_997401.1; NP_001291278.1). Based on the choice of the immunizing peptide there is no expected cross-reactivity with the other subunits.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

Goat anti-PRKACA Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Goat anti-PRKACA Antibody - Protein Information

Name PRKACA



Synonyms PKACA

Function

December dates a large number of substrates in the system and the nucleus (Dub Med. 49
Phosphorylates a large number of substrates in the cytoplasm and the nucleus (PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/15642694" target="_blank">15642694, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/15905176" target="_blank">15905176, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/16387847" target="_blank">16387847, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/17333334" target="_blank">17333334, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/17565987" target=" blank">17565987, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/17693412" target=" blank">17693412, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/18836454" target=" blank">18836454, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/19949837" target=" blank">19949837, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/20356841" target=" blank">20356841, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/21085490" target=" blank">21085490, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/21514275" target=" blank">21514275, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/21812984" target=" blank">21812984, PubMed: <a< td=""></a<>
href="http://www.uniprot.org/citations/31112131" target=" blank">31112131).
Phosphorylates CDC25B, ABL1, NFKB1, CLDN3, PSMC5/RPT6, PJA2, RYR2, RORA, SOX9 and VASP
(PubMed: 15642694 ,
PubMed: 15042094 , PubMed: 15042094 ,
PubMed: 16387847 ,
PubMed: 17333334 ,
PubMed: 17565987 ,
PubMed: 17693412 ,
PubMed: 18836454 ,
PubMed: 19949837 ,
PubMed: 20356841 ,
PubMed: 21085490 ,
PubMed: 21514275 ,
PubMed: 21812984).
Regulates the abundance of compartmentalized pools of its regulatory subunits through
phosphorylation of PJA2 which binds and ubiquitinates these subunits, leading to their subsequent
proteolysis (PubMed: <a <="" href="http://www.uniprot.org/citations/21423175" td="">
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: <a< td=""></a<>
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for</a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition</a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <="" href="http://www.uniprot.org/citations/19949837" td=""></a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of</a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen;</a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of</a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha</a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates</a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha</a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:15642694, PubMed:<a< td=""></a<></a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:<a< td=""></a<></a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:15642694, PubMed:<a< td=""></a<></a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:15642694, PubMed:20356841). Prevents the antiproliferative and anti-invasive effects of alpha- difluoromethylornithine in breast cancer cells</a </a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:15642694, PubMed:20356841). Prevents the</a </a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:15642694, PubMed:20356841). Prevents the antiproliferative and anti-invasive effects of alpha- difluoromethylornithine in breast cancer cells when activated (PubMed:<a <br="" href="http://www.uniprot.org/citations/1733334">target="_blank">17333334). RYR2 channel activity is potentiated by phosphorylation in</a </a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:15642694, PubMed:20356841). Prevents the antiproliferative and anti-invasive effects of alpha- difluoromethylornithine in breast cancer cells when activated (PubMed:<a <br="" href="http://www.uniprot.org/citations/1733334">target="_blank">17333334). RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased frequency of store</a </a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:15642694. Prevents the antiproliferative and anti-invasive effects of alpha- difluoromethylornithine in breast cancer cells when activated (PubMed:<a <br="" href="http://www.uniprot.org/citations/1733334">target="_blank">1733334). RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased frequency of store overload-induced Ca(2+) release (SOICR) characterized by an increased rate of Ca(2+) release</a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:20356841). Prevents the antiproliferative and anti-invasive effects of alpha- difluoromethylornithine in breast cancer cells when activated (PubMed:<a <br="" href="http://www.uniprot.org/citations/1733334">target="_blank">1733334). RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased frequency of store overload-induced Ca(2+) release (SOICR) characterized by an increased rate of Ca(2+) release and propagation velocity of spontaneous Ca(2+) waves, despite reduced wave amplitude and</a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:20356841). Prevents the antiproliferative and anti-invasive effects of alpha- difluoromethylornithine in breast cancer cells when activated (PubMed:<a <br="" href="http://www.uniprot.org/citations/1733334">target="_blank">1733334). RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased frequency of store overload-induced Ca(2+) release (SOICR) characterized by an increased rate of Ca(2+) release and propagation velocity of spontaneous Ca(2+) waves, despite reduced wave amplitude and resting cytosolic Ca(2+) (PubMed:<a <="" href="http://www.uniprot.org/citations/17693412" td=""></a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:15642694, PubMed:20356841). Prevents the antiproliferative and anti-invasive effects of alpha- difluoromethylornithine in breast cancer cells when activated (PubMed:<a <br="" href="http://www.uniprot.org/citations/1733334">target="_blank">1733334). RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased rate of Ca(2+) release and propagation velocity of spontaneous Ca(2+) waves, despite reduced wave amplitude and resting cytosolic Ca(2+) (PubMed:<a <br="" href="http://www.uniprot.org/citations/17693412">target="_blank">17693412). PSMC5/RPT6 activation by phosphorylation stimulates</a </a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:15642694, PubMed:20356841, Prevents the antiproliferative and anti-invasive effects of alpha- difluoromethylornithine in breast cancer cells when activated (PubMed:<a <br="" href="http://www.uniprot.org/citations/1733334">target="_blank">17333334). RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased frequency of store overload-induced Ca(2+) release (SOICR) characterized by an increased rate of Ca(2+) release and propagation velocity of spontaneous Ca(2+) waves, despite reduced wave amplitude and resting cytosolic Ca(2+) (PubMed:<a <br="" href="http://www.uniprot.org/citations/17693412">target="_blank">17693412). PSMC5/RPT6 activation by phosphorylation stimulates proteasome (PubMed:<a <="" href="http://www.uniprot.org/citations/17565987" td=""></a </a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:20356841). Prevents the antiproliferative and anti-invasive effects of alpha- difluoromethylornithine in breast cancer cells when activated (PubMed:<a <br="" href="http://www.uniprot.org/citations/1733334">target="_blank">17333334). RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased frequency of store overload-induced Ca(2+) release (SOICR) characterized by an increased rate of Ca(2+) release and propagation velocity of spontaneous Ca(2+) waves, despite reduced wave amplitude and resting cytosolic Ca(2+) (PubMed:<a <br="" href="http://www.uniprot.org/citations/17693412">target="_blank">17693412). PSMC5/RPT6 activation by phosphorylation stimulates proteasome (PubMed:<a <br="" href="http://www.uniprot.org/citations/17565987">target="_blank">17565987). Negatively regulates tight junctions (TJs) in ovarian cancer cells</a </a
proteolysis (PubMed: <a <br="" href="http://www.uniprot.org/citations/21423175">target="_blank">21423175). RORA is activated by phosphorylation (PubMed: 21514275). Required for glucose- mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts (PubMed:<a <br="" href="http://www.uniprot.org/citations/19949837">target="_blank">19949837). Involved in chondrogenesis by mediating phosphorylation of SOX9 (By similarity). Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP (PubMed:15642694, PubMed:20356841, Prevents the antiproliferative and anti-invasive effects of alpha- difluoromethylornithine in breast cancer cells when activated (PubMed:<a <br="" href="http://www.uniprot.org/citations/1733334">target="_blank">17333334). RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased frequency of store overload-induced Ca(2+) release (SOICR) characterized by an increased rate of Ca(2+) release and propagation velocity of spontaneous Ca(2+) waves, despite reduced wave amplitude and resting cytosolic Ca(2+) (PubMed:<a <br="" href="http://www.uniprot.org/citations/17693412">target="_blank">17693412). PSMC5/RPT6 activation by phosphorylation stimulates proteasome (PubMed:<a <="" href="http://www.uniprot.org/citations/17565987" td=""></a </a </a



binding (PubMed: <a href="http://www.uniprot.org/citations/15642694"

target=" blank">15642694). Required for phosphorylation of GLI transcription factors which inhibits them and prevents transcriptional activation of Hedgehog signaling pathway target genes (By similarity). GLI transcription factor phosphorylation is inhibited by interaction of PRKACA with SMO which sequesters PRKACA at the cell membrane (By similarity). Involved in embryonic development by down-regulating the Hedgehog (Hh) signaling pathway that determines embryo pattern formation and morphogenesis most probably through the regulation of OFD1 in ciliogenesis (PubMed:33934390). Prevents meiosis resumption in prophase-arrested oocytes via CDC25B inactivation by phosphorylation (By similarity). May also regulate rapid eye movement (REM) sleep in the pedunculopontine tegmental (PPT) (By similarity). Phosphorylates APOBEC3G and AICDA (PubMed: 16387847, PubMed:18836454). Phosphorylates HSF1; this phosphorylation promotes HSF1 nuclear localization and transcriptional activity upon heat shock (PubMed:21085490). Acts as a negative regulator of mTORC1 by mediating phosphorylation of RPTOR (PubMed:31112131).

Cellular Location

Cytoplasm. Cell membrane. Membrane; Lipid-anchor. Nucleus. Mitochondrion {ECO:000250|UniProtKB:P05132}. Note=Translocates into the nucleus (monomeric catalytic subunit). The inactive holoenzyme is found in the cytoplasm. Distributed throughout the cytoplasm in meiotically incompetent oocytes. Associated to mitochondrion as meiotic competence is acquired. Aggregates around the germinal vesicles (GV) at the immature GV stage oocytes (By similarity). Colocalizes with HSF1 in nuclear stress bodies (nSBs) upon heat shock (PubMed:21085490) Recruited to the cell membrane through interaction with SMO (By similarity). {ECO:0000250|UniProtKB:P05132, ECO:0000269|PubMed:21085490}

Tissue Location

Isoform 1 is ubiquitous. Isoform 2 is sperm- specific and is enriched in pachytene spermatocytes but is not detected in round spermatids.

Goat anti-PRKACA Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

Goat anti-PRKACA Antibody - Images